Ad scientiam

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Ad scientiam sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials 2 currently recruiting 1 completed upper quartile by trial count

Ad scientiam: 5 sponsored US clinical trials, 2 recruiting.

Ad scientiam sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. The most-studied condition in this pipeline is Multiple Sclerosis, with 2 trials.

Upper-quartile sponsor footprint

Ad scientiam sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Ad scientiam pipeline

2 recruiting of 5 indexed (40% open); 1 completed (20%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Multiple Sclerosis (2 trials), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Ad scientiam: open-pipeline peers nationwide

Peers matched on 5 registered trials and 40% open enrollment, not the therapeutic-area sidebar.

Ad scientiam sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%10%20%30%40%50% Total trials Recruiting share Ad scientiam4YouandMeAbbott Rapid DxAccess Business GroupAcera SurgicalAlto NeuroscienceBonafide HealthBrooks RehabilitationC4 Therapeutics
Ad scientiam sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ad scientiam sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 trials (± recruiting share)

Sponsors near 40% open enrollment (± trial volume)

What to do with this Ad scientiam page

5 registered trials is a research-attention snapshot, not an endorsement of Ad scientiam or any single study.

  • 2 of Ad scientiam's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Multiple Sclerosis is the condition Ad scientiam studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ad scientiam pipeline card: 5 registered trials from official public datasets.Report a data error.